Show simple item record

dc.contributor.authorHoulihan, Robert H.
dc.contributor.authorKennedy, Michael H.
dc.contributor.authorKulesher, Robert R.
dc.contributor.authorLemon, Stephenie C.
dc.contributor.authorWickerham, D. Lawrence
dc.contributor.authorHsieh, Chung-Cheng
dc.contributor.authorAltieri, Dario C.
dc.date2022-08-11T08:10:20.000
dc.date.accessioned2022-08-23T17:04:57Z
dc.date.available2022-08-23T17:04:57Z
dc.date.issued2010-08-22
dc.date.submitted2011-11-09
dc.identifier.citationCancer. 2010 Aug 1;116(15):3569-76. <a href="http://dx.doi.org/10.1002/cncr.25230">Link to article on publisher's site</a>
dc.identifier.issn0008-543X (Linking)
dc.identifier.doi10.1002/cncr.25230
dc.identifier.pmid20564133
dc.identifier.urihttp://hdl.handle.net/20.500.14038/44749
dc.description.abstractBACKGROUND: The purpose of this study was to examine factors influencing a woman's decision to participate in a breast cancer prevention clinical trial. Nine healthcare organizations in Massachusetts cooperated in the present project. METHODS: The authors performed a case-control study to compare responses between the study group (Study of Tamoxifen and Raloxifene [STAR] trial eligible, but not enrolled) and the control group (STAR trial participants) on 12 factors previously identified as barriers to accrual for clinical trials. Eight hypotheses were tested using multiple logistic regression to estimate the strength of the association for each factor on the dependent variable (study participation). RESULTS: The study samples were similar to the general population of eligible breast cancer prevention clinical trial subjects in the counties where the participating organizations were located, the state of Massachusetts, and nationally published STAR trial data. Results of a mailed questionnaire showed that when adjusting for subject demographics, and in the presence of other questions, 4 factors significantly influenced a woman's decision to enroll onto a breast cancer prevention clinical trial more than other eligible subjects: 1) clinician expertise and qualifications (P=.012; odds ratio [OR], 4.903; 95% confidence interval [CI], 1.41-17.04); 2) personal desire to participate (P=.033; OR, 3.16; 95% CI, 1.10-9.06); 3) perceived value of the trial (P=.020; OR, 2.92; 95% CI, 1.18-7.21); and 4) level of trial inconvenience (P=.002; OR, 0.10; 95% CI, 0.02-0.44). CONCLUSIONS: Addressing these issues in the relationship between patients and clinicians should improve accrual to breast cancer prevention clinical trials.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=20564133&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3077438/pdf/nihms175838.pdf
dc.subjectAdult
dc.subjectBreast Neoplasms
dc.subjectCase-Control Studies
dc.subject*Clinical Trials as Topic
dc.subjectFemale
dc.subjectHumans
dc.subjectMiddle Aged
dc.subject*Patient Selection
dc.subjectPhysician-Patient Relations
dc.subjectQuestionnaires
dc.subjectBehavioral Disciplines and Activities
dc.subjectBehavior and Behavior Mechanisms
dc.subjectCommunity Health and Preventive Medicine
dc.subjectNeoplasms
dc.subjectPreventive Medicine
dc.titleIdentification of accrual barriers onto breast cancer prevention clinical trials: a case-control study
dc.typeArticle
dc.source.journaltitleCancer
dc.source.volume116
dc.source.issue15
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/prevbeh_pp/170
dc.identifier.contextkey2340860
html.description.abstract<p>BACKGROUND: The purpose of this study was to examine factors influencing a woman's decision to participate in a breast cancer prevention clinical trial. Nine healthcare organizations in Massachusetts cooperated in the present project.</p> <p>METHODS: The authors performed a case-control study to compare responses between the study group (Study of Tamoxifen and Raloxifene [STAR] trial eligible, but not enrolled) and the control group (STAR trial participants) on 12 factors previously identified as barriers to accrual for clinical trials. Eight hypotheses were tested using multiple logistic regression to estimate the strength of the association for each factor on the dependent variable (study participation).</p> <p>RESULTS: The study samples were similar to the general population of eligible breast cancer prevention clinical trial subjects in the counties where the participating organizations were located, the state of Massachusetts, and nationally published STAR trial data. Results of a mailed questionnaire showed that when adjusting for subject demographics, and in the presence of other questions, 4 factors significantly influenced a woman's decision to enroll onto a breast cancer prevention clinical trial more than other eligible subjects: 1) clinician expertise and qualifications (P=.012; odds ratio [OR], 4.903; 95% confidence interval [CI], 1.41-17.04); 2) personal desire to participate (P=.033; OR, 3.16; 95% CI, 1.10-9.06); 3) perceived value of the trial (P=.020; OR, 2.92; 95% CI, 1.18-7.21); and 4) level of trial inconvenience (P=.002; OR, 0.10; 95% CI, 0.02-0.44).</p> <p>CONCLUSIONS: Addressing these issues in the relationship between patients and clinicians should improve accrual to breast cancer prevention clinical trials.</p>
dc.identifier.submissionpathprevbeh_pp/170
dc.contributor.departmentDepartment of Medicine, Division of Preventive and Behavioral Medicine
dc.contributor.departmentDepartment of Cancer Biology
dc.source.pages3569-76


This item appears in the following Collection(s)

Show simple item record